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ABSTRACT
Previously, the authors have identified that c-Met mediates reactivation of the 
PI3K/AKT pathway following BRAF inhibitor treatment in BRAF (V600E) mutant 
anaplastic thyroid cancer, thereby contributing to the acquired drug resistance. 
Therefore dual inhibition of BRAF and c-Met led to sustained treatment response, 
thereby maximizing the specific anti-tumor effect of targeted therapy. The present 
study goes one step further and aims to investigate the effect of acquired resistance of 
BRAF inhibitor on epithelial-to-mesenchymal transition (EMT) in BRAF mutant thyroid 
cancer cells and the effect of dual inhibition from combinatorial therapy. Two thyroid 
cancer cell lines, 8505C and BCPAP were selected and treated with BRAF inhibitor, 
PLX4032 and its effect on EMT were examined and compared. Further investigation 
was carried out in orthotopic xenograft mouse models. Unlike BCPAP cells, the BRAF 
inhibitor resistant 8505C cells showed increased expressions of EMT related markers 
such as vimentin, β-catenin, and CD44. The combinatorial treatment of PLX4032 
and PHA665752, a c-Met inhibitor reversed EMT. Similar results were confirmed  
in vivo. c-Met-mediated reactivation of the PI3K/AKT pathway contributes to the drug 
resistance to PLX4032 in BRAF (V600E) mutant anaplastic thyroid cancer cells and 
further promotes tumor cell migration and invasion by upregulated EMT mechanism. 
Dual inhibition of BRAF and c-Met leads to reversal of EMT, suggesting a maximal 
therapeutic response.
INTRODUCTION
Thyroid cancer is the most common endocrinologic 
malignancy. Multiple genetic mutations or alterations are 
involved in the tumorigenesis of thyroid cancer, BRAF 
(V600E) mutation being the most common [1,2]. BRAF 
(V600E) mutation causes sustained BRAF kinase activity 
leading to constitutive activation of MAPK cascade 
pathway, and BRAF (V600E) mutation bearing thyroid 
cancer presents aggressive clinicopathologic features. 
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BRAF (V600E) mutation is also commonly detected in 
other tumors such as melanoma and colorectal cancer 
[3,4]. In malignant melanoma, a FDA approved selective 
BRAF inhibitor vemurafenib (PLX4032) has shown high 
treatment response [5]. However, unlike in metastatic 
melanoma, the treatment effects of vemurafenib in BRAF 
(V600E) mutant thyroid cancer are often insignificant.
Previously, the authors have elucidated to a 
considerable level the causative mechanism underlying 
acquired resistance to BRAF inhibition in BRAF 
(V600E) mutant thyroid cancer [6]. The previous study 
demonstrated differential treatment responses of BRAF 
inhibition in different types of thyroid cancer harboring 
BRAF (V600E) mutation. On the contrary to the favorable 
treatment response in BCPAP, a papillary thyroid cancer 
(PTC) cell line, decreased treatment response was noted 
in 8505C, an anaplastic thyroid cancer (ATC) cell line. It 
has been identified that c-Met mediates reactivation of the 
PI3K/AKT pathway thereby contributing to the acquired 
resistance of BRAF inhibition in BRAF mutant ATC 
cells. Therefore dual inhibition of BRAF and c-Met led 
to sustained treatment response, thereby maximizing the 
specific anti-tumor effect of targeted therapy.
Epithelial-to-mesenchymal transition (EMT) is 
a process where epithelial cells demonstrate changes in 
their morphology and motile behavior as they differentiate 
into mesenchymal cells. During the EMT, epithelial cells 
lose cell to cell contact, undergo cytoskeleton remodeling, 
acquire expression of mesenchymal components, and 
manifest a migratory phenotype [7,8]. It is generally 
accepted that EMT plays a crucial role in the migration, 
invasion, and metastasis of cancer.
On the basis of our previous findings, this present 
study goes one step further and aims to investigate the 
effect of acquired resistance of BRAF inhibitor on EMT 
in BRAF mutant thyroid cancer cells. Also we investigated 
the effect of dual inhibition from combinatorial therapy on 
EMT in BRAF inhibitor-resistant ATC.
RESULTS
Differential effect against EMT is shown in 
different BRAF (V600E) mutant thyroid cancer 
cell lines to PLX4032 treatment
To evaluate the differential effects of EMT in 
two different BRAF (V600E) mutant thyroid cancers, 
PLX4032 was treated to 8505C and BCPAP cells which 
have each been previously verified as BRAF inhibitor-
resistant and -sensitive cell lines, respectively. Simple 
examination under light microscopy (magnification x20) 
after PLX4032 treatment revealed distinct morphological 
differences between 8505C and BCPAP cells. That is, the 
8505C cells presented long, spindle shaped phenotypes 
resembling mesenchymal cell morphology whereas the 
BCPAP cells were more closely aggregated together with 
more round shapes suggesting epithelial cell phenotype 
(Figure 1A). From the live wound healing assays of 8505C 
and BCPAP cell lines after PLX4032 treatment, the rate 
of wound closure was prominently faster in 8505C cells 
(Figure 1B, Supplementary Video S1). This increased 
EMT trend could also be verified in transwell migration 
assay, where cell invasion was significantly increased in 
8505C cells compared to BCPAP cells (Figure 1C).
Western blot analysis in 8505C and BCPAP cells 
following PLX4032 treatment revealed that p-c-Met and 
p-AKT levels were significantly increased in 8505C cells 
together with increased levels of vimentin, β-catenin, and 
CD44. These markers however, were unchanged in BCPAP 
cells (Figure 2A). Increases of EMT related markers in 
8505C were also confirmed in immunofluorescence 
confocal microscopy where vimentin, β-catenin, and 
CD44 expressions were all increased in 8505C cells 
after PLX4032 treatment whereas there was no change in 
BCPAP cells (Figure 2B–2D).
PLX4032 treatment increases EMT via over-
expression of PI3K/AKT pathway mediated by 
p-c-Met in 8505C
In order to investigate the EMT changes of 8505C 
cells under BRAF inhibition, PLX4032 was treated to 
8505C cells at different times and different concentrations. 
According to increased treatment times of PLX4032, p-c-
Met expression was significantly increased followed by 
increased levels of p-AKT (Figure 3A). Also, markers 
of EMT such as vimentin, β-catenin, and CD44 were 
consequently increased. The p-c-Met mediated PI3K/AKT 
pathway activation leading to over-expression of EMT 
markers were also confirmed after treatment of PLX4032 
in a dose-dependent manner (Figure 3B).
Dual inhibition of BRAF and c-Met has reversal 
effect on EMT in 8505C
When c-Met was knocked down and PLX4032 
treated with increasing times, all vimentin, β-catenin, 
and CD44 expression levels were markedly decreased, 
together with low expressions of p-c-Met, p-AKT, and 
p-ERK (Figure 4A).
In accordance with the previous results, vimentin, 
β-catenin, and CD44 were over-expressed together 
with increased levels of p-c-Met and p-AKT, following 
PLX4302 treatment. Whereas there was no change except 
for the decrease of p-c-Met upon PHA665752 treatment, 
all expression levels of p-c-Met, p-AKT, p-ERK, and EMT 
related markers were decreased following combinatorial 
treatment of PLX4032 with PHA665752 (Figure 4B).
From the transwell migration assay (Figure 4C), cell 
invasion was prominent in PLX4032 single treatment condition 
but was not increased following combinatorial treatment of 
PLX4032 and PHA665752. Under immunofluorescence 
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Figure 1: Differential effect against EMT in BRAF (V600E) mutant thyroid cancer cell lines 8505C and BCPAP to 
PLX4032 treatment. (A) Observation under light microscopy (x20) after treatment with 1 μM PLX4032 for 9 h. (B) Live wound healing 
assay after treatment with 1 μM PLX4032 for 9 h. **p < 0.01. (C) Analysis of cell invasion with transwell migration assay after treatment 
with 1 μM PLX4032 for 9 h. ***p < 0.001.
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Figure 2: Expression of EMT related markers in 8505C and BCPAP to 1 μM PLX4032 treatment for 9 h. (A) Western 
blot analysis after PLX4032 treatment in 8505C cells. (B) Immunofluorescence confocal microscopy of vimentin. (C) Immunofluorescence 
confocal microscopy of β-catenin. (D) Immunofluorescence confocal microscopy of CD44.
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confocal microscopic examination, vimentin, β-catenin, and 
CD44 expressions were all increased following PLX4032 
single treatment however, all markers were barely detectable 
following combinatorial treatment of PLX4032 and 
PHA665752 (Figure 4D–4F). Furthermore, changes in the 
intracellular network of vimentin according to each drug 
treatment condition were investigated under 3D confocal 
microscopy (Figure 4G). That is, the vimentin expression in 
PLX4032 single treatment condition revealed extensively 
distributed vimentin network, whereas the intracellular 
vimentin was reorganized into perinuclear aggregates 
following PLX4032 and PHA665752 combinatorial treatment.
Effects on EMT following PLX4032 and 
PHA665752 treatment in a xenograft mouse 
model orthotopically injected with 8505C
The tendencies shown in in vitro experiments 
were also confirmed in in vivo animal studies. In 
concordance with our previous study results, the tumor 
volumes and weights were paradoxically larger in the 
mice of PLX4032 single treatment group compared to 
the control group, but both values were significantly 
smaller in the combinatorial treatment group (data not 
shown). Considering these changes in tumor size for each 
treatment groups, EMT protein expression levels in tumor 
specimens of each group were analyzed. All vimentin, 
β-catenin, and CD44 expressions were increased in 
PLX4032 single treatment group but the levels of EMT 
markers were considerably decreased in combinatorial 
drug treatment group (Figure 5A). 
Histopathological analysis by hematoxylin and eosin 
(H & E) staining from tumor specimens of each treatment 
group revealed aggressive pathologic features in PLX4032 
single treatment group and favorable pathologic features 
in combinatorial drug treatment group, with reference to 
control (Figure 5B). More specifically, the PLX4032 single 
treatment group showed large sized tumor mass with local 
infiltration but the combinatorial treatment group showed 
small sized tumor mass with extensive necrosis and partial 
formation of fibrotic tumor capsule under low power 
examination. The control group presented medium sized 
mass showing infiltration into adjacent skeletal muscle 
with only focal necrosis. Under high power microscopic 
examination, viable anaplastic tumor cells were noted in 
control and PLX4032 single treatment groups however, 
the combinatorial treatment group presented cellular 
degenerative changes and decreased cell viability with 
extensive necrosis.
Immunohistochemistry demonstrating intratumoral 
EMT-related proteins expression levels of each treatment 
groups confirmed high detection levels of all vimentin, 
β-catenin, and CD44 in PLX4032 single treatment 
group compared to control (Figure 5C). However the 
expressions of all EMT markers were markedly decreased 
in combinatorial drug treatment group.
Figure 3: PLX4032 treatment increases EMT via over-expression of PI3K/AKT pathway mediated by p-c-Met in 
8505C. (A) Western blot analysis after treatment of 1 μM PLX4032 of increasing treatment times in 8505C cells. (B) Western blot analysis 
after treatment of PLX4032 of increasing dosages for 6 h in 8505C cells.
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Figure 4: Dual inhibition of BRAF and c-Met has reversal effect on EMT in 8505C cells (1 μM PLX4032, 0.5 μM 
PHA665752). (A) 8505C cells transfected with small interfering RNA (siRNA) of c-Met or negative control siRNA were treated with 
1 μM PLX4032 for 3,6, and 9 h. (B) Western blot analysis after different drug treatment conditions for 9 h. (C) Transwell migration assay of 
8505C cells under each different treatment conditions. **p < 0.01. (D) Immunofluorescence confocal microscopic examination of vimentin 
expression under different drug treatment conditions. (E) Immunofluorescence confocal microscopic examination of β-catenin expression 
under different drug treatment conditions. (F) Immunofluorescence confocal microscopic examination of CD44 expression under different 
drug treatment conditions. (G) 3D confocal microscopic examination of intracellular vimentin network under different drug treatment 
conditions (Blue, nucleus; red, f-actin; green, vimentin).
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DISCUSSION
ATC accounts less than 5% of all thyroid carcinomas 
and is considered as a highly virulent malignancy with an 
extremely poor prognosis [9,10]. It presents an overall 
median survival time of 6 months despite the best 
multidisciplinary care and it is associated with an even 
graver prognosis in metastatic disease [11]. Even the 
differentiated thyroid carcinomas which generally have 
an excellent prognosis, show disappointing treatment 
outcomes in patients with extensive local invasion or 
distant metastases [12,13]. The 5-year survival rate is 
merely 50% in patients who presents distant metastases 
at initial diagnosis [14,15]. The EMT mechanism is 
considered important in the initiation and promotion 
of cancer invasion and metastasis. The hallmarks of 
EMT include downregulation of epithelial markers and 
upregulation of mesenchymal markers, together with 
morphological and functional changes of the cell. So 
as the epithelial cells lose their apical polarity and cell-
cell contact and acquire spindle-shaped, fibroblastic cell 
phenotypes with increased cell motility, expressions of 
N-cadherin, vimentin, fibronectin, and osteopontin are 
increased while expression of E-cadherin is decreased 
[16–20]. Also, transcription factors including Snail, 
Slug, and Twist are activated with nuclear localization of 
β-catenin and increased expression of CD44, a stemness 
marker implicated in migration and metastasis of cancer 
cells [21].
Multiple complex mechanisms are involved in the 
EMT process and evidence suggests that the PI3K/AKT 
signaling pathway plays a mechanistically important 
role in migration and progression of tumors including 
thyroid cancer [22,23]. In particular, AKT has shown to 
activate cell migration and invasion in thyroid cancer 
cell lines [20,24]. That is, intranuclear accumulation of 
p-AKT and nuclear exclusion of p27 to the cytoplasm 
was directly associated with the invasiveness of thyroid 
cancer cells with acquisition of mesenchymal phenotype, 
thereby suggesting AKT activation is involved in direct 
induction of EMT. Furthermore, this has been suggested 
by many others where levels of Snail and Twist and AKT 
phosphorylation were also positively correlated in oral 
squamous cell carcinoma and prostate carcinoma [25–27]. 
In head and neck squamous cell carcinoma, PI3K/AKT 
activation degrades E-cadherin and promotes cell invasion 
and migration [28,29]. In gastric cancer and breast cancer 
cells, inhibition of PI3K/AKT signaling pathway repressed 
MMP2/MMP9 activation and reduced EMT [30,31]. 
The PI3K/AKT pathway positively regulates the Wnt/β-
catenin signaling pathway by the increase of intracellular 
β-catenin levels from AKT phosphorylation which then 
induces the movement of β-catenin into the nucleus to bind 
with TCF/LEF. This binding ultimately leads to activation 
of genes targeted to induce EMT [29,32]. Also, there have 
been earlier reports that hepatocyte growth factor (HGF) 
and its receptor c-Met are overexpressed in thyroid cancer 
and HGF treatment increases thyroid cancer cell motility 
through overexpression of EMT markers [33–36]. The 
PI3K/AKT pathway is also closely related, since it is 
indispensable for HGF-induced EMT [37,38].
In the previous study, the c-Met mediated 
reactivation of PI3K/AKT pathway following PLX4032 
treatment was identified as the key mechanism underlying 
the resistance to BRAF inhibition in ATC [6]. In the 
present study, it could be confirmed that the acquired 
resistance mechanism also induced the EMT process. 
That is, unlike the BRAF inhibitor-sensitive BCPAP 
cells, the BRAF inhibitor-resistant 8505C cells presented 
upregulated EMT following PLX4032 treatment. The 
fundamental causative mechanism for this differential 
drug response in different types of BRAF (V600E) mutant 
thyroid cancer is unknown and is beyond the scope of 
this study but further investigation is warranted. Both 
morphological and functional features of mesenchymal 
phenotypes were verified, together with elevated 
expression of EMT related markers such as vimentin, 
β-catenin, and CD44 (Figures 1, 2). Furthermore, the 
upregulation of EMT markers following PLX4032 
treatment in 8505C were in accordance to increased 
levels of p-c-Met and p-AKT (Figure 3) and conversely, 
expressions of these EMT related markers were uniformly 
decreased both by c-Met knockout and c-Met inhibitor 
treatment together with BRAF inhibition (Figure 4). The 
EMT reversal effect following combinatorial treatment 
of PLX4032 and PHA665752 could also be confirmed 
by the decreased cell invasion ability (Figure 4). Besides 
the expressional changes, the intracellular network 
reorganization of vimentin from EMT is also considered 
important [39]. In accordance to previous reports, further 
investigation of the vimentin network revealed generalized 
intracellular distribution of vimentin in upregulated EMT 
state however, the intracellular vimentin was presented 
as juxtanuclear caps in EMT reversal status (Figure 4G). 
Upregulation of EMT caused by the predilection for PI3K/
AKT pathway following BRAF inhibition is plausible, 
considering the aforementioned studies reporting close 
associations between HGF/c-Met, PI3K/AKT signaling 
and EMT. Already preliminary results of combinatorial 
treatment of BRAF inhibitor with an AKT inhibitor in this 
setting confirming similar therapeutic responses have been 
obtained (data not shown). The results were also verified 
in vivo (Figure 5).
There have been previous reports that BRAF 
(V600E) mutation stimulates migration and invasion of 
thyroid cancer cells, through the increased expression 
of EMT-related markers via a MEK/ERK-dependent 
mechanism and that these processes together with tumor 
proliferation can be inhibited by BRAF inhibitor PLX4720 
treatment [40,41]. This however, may not always be the 
case, as has been demonstrated in this present study. This 
discrepancy in contrary results may be due to the fact that 
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Figure 5: Effects on EMT following PLX4032 and PHA665752 treatment in a xenograft mouse model orthotopically 
injected with 8505C cells. Orthotopic injection of 8505C cells in thyroid glands of BALB/c nude mice were done and randomly divided 
into four groups with different treatment conditions as follows; DMSO (20 mg/kg/day), PLX4032 (20 mg/kg/day), PHA665752 (10 mg/
kg/day), and combinatorial PLX4032 (20 mg/kg/day) and PHA665752 (10 mg/kg/day) treatment. (A) Western blot analysis of intratumoral 
protein expression from the obtained tumor specimens in each group. (B) Histopathological analysis by H & E staining from tumor tissue 
samples obtained from mice of each group. (C) Immunohistochemistry of tumor tissues from each treatment group.
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we have used a different, more clinically available BRAF 
inhibitor drug, PLX4032 (vemurafenib) and at suboptimal 
dosage, but nevertheless should receive more attention 
since the BRAF inhibitor is not always sensitive in 
BRAF (V600E) mutant thyroid cancer in reality. Various 
underlying resistance mechanisms against BRAF inhibitor 
therapy in thyroid cancer have been investigated in 
previous studies [6, 42]. That is, our findings in the present 
study would be more applicable to the concept of drug 
resistance against BRAF inhibitor and would pose more 
valuable clinical implications. The interesting fact that 
BRAF inhibition in 8505C cells induces EMT from our 
study suggests that sustained BRAF inhibitor treatment 
in thyroid cancer would do more harm than good, which 
raises an important clinical issue.
Recently it has been shown in numerous reports 
that aberrant activation of EMT and an associated cancer 
stem cell phenotype are considered a major cause of drug 
therapy resistance in aggressive solid tumors such as 
pancreatic cancer, lung cancer, and melanoma, particularly 
emphasizing the important role of the EMT-activator, 
ZEB1 in conferring stemness and resistance [43–46]. This 
EMT-related phenotypic change and tumor cell plasticity 
shown in the present study therefore, can be suggested 
furthermore as another acquired resistance mechanism to 
BRAF inhibitor, so further in-depth studies are warranted 
to elucidate the precise underlying mechanism.
In summary, this study demonstrates that the 
previously confirmed BRAF inhibitor-resistant 8505C 
cells showed increased EMT response via acquired 
resistance mechanism mediated by the increased 
expression of c-Met. Accordingly, the combinatorial 
treatment of BRAF inhibitor and c-Met inhibitor reversed 
EMT. To our knowledge, this is the first report showing 
that acquired drug resistance to BRAF inhibition promotes 
not only tumor progression and proliferation, but also 
migration and invasion of BRAF (V600E) mutant thyroid 
cancer cells through upregulated EMT induced by c-Met-
mediated AKT activation. Therefore combinatorial 
multi-targeted therapy could overcome the limitation 
of single agent therapy and maximize anti-tumor effect. 
Furthermore it is expected that the PI3K/AKT signaling 
pathway will have greater clinical implications by 
attracting widespread attention as a potential target for the 
prevention and treatment of metastatic cancer. 
MATERIALS AND METHODS
Cell culture
BRAF (V600E) mutant thyroid cancer cell lines, 
8505C and BCPAP were obtained from DSMZ (German 
collection of microorganisms and cell cultures, Braunschweig, 
Germany) and were maintained in 10% RPMI medium 
(Lonza, Wakersville, USA) and cultured in a humidified 
incubator at 37°C in an atmosphere containing 5% CO2.
Time-lapse microscopy for wound healing assay
The in-situ wound healing potentials of thyroid 
cancer cells were monitored by live cell imaging 
microscopy (DMI6000B, Leica, Bensheim, Germany). 
8505C and BCPAP cells (1 × 105 cells/well) were seeded 
in a 6-well plate and incubated for 24 h. When seeded cells 
were stable in the plate, 8505C and BCPAP cells were each 
treated with 1 μM PLX4032, and wound was carefully 
made across the cell monolayer by a plastic pipette tip. The 
medium was refreshed with complete medium. 1 μg/ ml 
mitomycin C was treated to the cells to prevent the cell 
proliferation effect. Cells were then incubated in a live cell 
chamber (Chamlid HX, LCI, Seoul, Republic of Korea), 
connected to a temperature and CO2 controllers (Heating 
& Cooling system/CU-301 and Gas mixer/FC-5N, LCI, 
Seoul, Republic of Korea). The migratory behavior of cells 
was monitored for 2 days after scratching and time-lapse 
sequential microscopic images were acquired at intervals 
of 30 min. After the complete acquisition of time-lapse live 
cell microscopic images, movies were made at 3 frames/
sec (scale bars represent 100 µm). Migration rates of 
8505C and BCPAP cells were determined by measuring 
the wound closure percentage as defined below: 
Wound closure (%) = (migrated cell surface area/ 
total surface area) x 100, migrated cell surface area = 
length of cell migration (mm) x 2 x length, total surface 
area = 2.4 mm x length. 
For each time frame, the experiments were repeated 
three times.
Transwell migration assay
Cell invasion was determined by transwell migration 
assay. First, 8505C and BCPAP cells (1 ×105 cells/well) 
were seeded in a 6-well plate and drug was treated for 
9 h. Meanwhile, 70 μl gel mixture of 1:1 ECM gel and 
0.2% RPMI was added in a 24-well transwell chamber 
(Corning, Kennebunk, USA) and was kept at 4°C. After 
9 h drug treatment, the cells in the 6-well plate were 
seeded (3 × 104 cells/100 μl) in the transwell chamber. The 
chamber was incubated for 6 h with 5% CO2 at 37°C and 
then non-migrant cells left on the upper section of the filter 
were removed using a cotton swab. Finally, attached cells 
at the lower section were stained with crystal violet and 
counted under a light microscope (magnification x 40).
Confirmation of EMT marker expression and 
c-Met inhibitor-induced reversal of EMT by 
western blot analysis
Thyroid cell lines were washed with phosphate-
buffered saline (PBS) and were treated with lysis buffer 
(10 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1 mM EDTA, 
1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 2 mM 
Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS, 
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0.5% deoxylcholate) (Invitrogen, Camarillo, USA) 
supplemented with 1 mM PMSF and protease inhibitors 
cocktail (Sigma-Aldrich, St. Louis, USA) and then 
harvested. The protein was centrifuged under 13,200 rpm 
for 10 min and the supernatant was used for Western blot 
analysis where the protein amount was quantified with 
Pierce BCA Protein Assay Kit (Thermo, Rockford, USA). 
The lysates were electrophoresed using 10% SDS-PAGE to 
separate proteins and electrotransferred to polyvinylidene 
fluoride membranes (Millipore, Schwalbach, Germany). 
An equal amount of protein (30 μg) was loaded per well 
and the proteins were transferred onto the following 
antibodies to be left at 4°C overnight incubation: p-c-
Met (1:1000), p-AKT (1:1000), p-ERK (1:1000), 
vimentin (1:1000), β-catenin (1:1000), CD44 (1:1000), 
and GAPDH (1:1000). The next day, it was thoroughly 
washed with TBS containing 0.1% Tween-20, and then 
reacted with secondary rabbit antibody (Jackson, West 
Grove, USA) and anti-mouse antibody (Jackson) to be 
visualized on X-ray film using SuperSignal West Pico 
Chemiluminescent Substrate (Thermo).
Immunofluorescence confocal microscopy
Cover glasses were coated in a 6-well plate and 
1 × 105 cells were seeded. After 24 h, drug was treated to 
the seeded cells for 9 h. Then the media was removed and 
the cells were washed twice with PBS. Cells were then 
fixed in 1% paraformaldehyde (PFA) at room temperature 
for 15 min and washed twice. Next the cells were blocked 
with mixture of PBS, 1% bovine serum albumin (BSA), 
and 10% normal goat serum for 1 h and then treated with 
the following primary antibodies, followed by overnight 
incubation: vimentin (1:200), β-catenin (1:200), and 
CD44 (1:200). The next day, it was thoroughly washed 
twice with PBS and then each reacted with the following 
secondary antibodies (1:500) for 2 h: Alexa Flour 488 
donkey anti-mouse antibody (Invitrogen) and Alexa Flour 
488 donkey anti-rabbit antibody (Life Technology). After 
further washing with PBS, 10 μl moutin was treated on 
the cover glasses and transferred to slides. The stained 
cells were then visualized with confocal microscopy (Carl 
Zeiss, Oberkochen, Germany) at 488 nm.
Transient transfection of c-Met and RNA 
interference (siRNA)
3 × 104 cells per well were seeded onto 6-well 
culture dishes containing 2 ml antibiotic-free medium 
supplemented with 10% fetal bovine serum (FBS). 
Next, 500 μl optimum and 10 μl RNAiMAX, and 500 μl 
optimum and 5 μl RNAi were mixed and left at room 
temperature for 5 min, and then mixed together. siRNAs 
for the control and c-Met (BIONEER sense: 100451 
antisense:100451) were then mixed and after 20 min, 
droplets of the mixture were applied at the cells and left to 
react for 6 h. Thereafter, the medium was changed to 10% 
FBS and penicillin-streptomycin supplemented medium 
and the cells were incubated at 37°C with 5% CO2 for 48 h. 
Subsequently PLX4032 was treated for 9 h and the cells 
were harvested and confirmed by Western blot analysis.
3D Confocal microscopy
8505C cells were plated on coverslips at a cell 
density of (1 × 105) in a 6-well plate with 18 mm cover 
slip and allowed to adhere overnight. On the following 
day, 8505C cells were incubated in serum starved medium 
for 24 h to induce cell cycle arrest. The cells were then 
fixed for 30 min with 4% PFA. Subsequently, the cells 
were washed three times with PBS and permeabilized with 
0.5% Triton X-100 for 15 min. The cells were washed 
three times with blocking buffer (PBS supplemented with 
0.1% BSA and 0.001% sodium azide) and incubated for 
30 min. The cells were further incubated for 30 min at 
22°C with primary antibodies at a 1:200 dilution. After 
primary serum incubation, the cells were washed three 
times with blocking buffer and incubated with secondary 
antibodies at a dilution ratio of 1:500 for 30 min at 22°C. 
Finally, the cells were washed again for three times with 
PBS. A nucleus staining solution with Hoechst 33342 (Cat 
#. H3570, Molecular Probes, Waltham, MA, USA) was 
added to a final concentration of 5 mg/mL. The confocal 
microscopic images were obtained using a confocal 
microscope (LSM-700, Carl Zeiss, Jena, Germany) with a 
63× objective and ZEN software (version 5.5.0.375, Carl 
Zeiss), which was designed for acquisition and processing 
of confocal microscopic images.
Orthotopic xenograft mouse model
8505C cells were harvested and 1 × 105 cells 
were suspended in 5 μl PBS which were then injected 
orthotopically in the right thyroid gland of male athymic 
nude BALB/c mice, aged 6 weeks (Orientbio Inc., 
Seongnam-si, Korea) with a 25 μl Hamilton syringe 
(Hamilton Company, Reno, NV). Tumor formation 
was examined at 3 weeks post injection, and the mice 
were randomly divided into four groups of four. The 
control group was treated with DMSO and the other 
3 groups were each injected with PLX4032, PHA665752, 
PLX4032 and PHA665752 combination respectively, 
3 times a week for 3 weeks. The mice were then 
euthanized and Western blot analysis, H&E staining, and 
immunohistochemistry analysis were conducted from 
specimens. All mice experiments were approved by the 
Committee for ethics in animal experiments of Yonsei 
University College of Medicine and all experimental 
mice were handled in accordance with the Guide for 
the care and use of laboratory animals in Department of 
laboratory animal resources, Yonsei University College 
of Medicine.
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Immunohistochemistry analysis
The tumor tissue specimens obtained from mice 
were processed for paraffin section and deparaffinized 
consequently with xylene and ethanol. Antigen retrieval 
was done for 15 min followed by reaction with H2O2 for 
10 min and blocking (10% normal goat serum + 0.01% 
BSA + dilution) for 1 h. The slides were then incubated 
overnight at 4°C with primary anti-vimentin, β-catenin, and 
CD44 antibody (1:200). Next, the slides were treated with 
secondary anti-rabbit antibodies (1:500) for 1 h and reacted 
using DAB histochemistry kit (Life technologies, Rockford, 
IL). Finally the slides were stained with hematoxylin and 
processed with mounting solution (DAKO) and visualized 
using a Nikon light microscope. Microscopic images were 
captured and processed using AxioCam digital microscope 
camera and AxioVision Image processing software (Carl 
Zeiss Vision, Oberkochen, Germany).
Statistical analysis
All data were obtained from triplicate independent 
experiments, and the parameters were represented as 
means ± SD. Student’s t-test and one-way ANOVA were 
performed using SPSS 20.0 statistical software (SPSS, 
Chicago, IL, USA). A p < 0.05 was considered statistically 
significant (*p < 0.05; **p < 0.01; ***p < 0.001).
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